The Effect of Vitamin K2 in Addition to Risedronate on the Patients with Postmenopausal Osteoporosis
Journal of the Korean Academy of Rehabilitation Medicine
; : 491-495, 2006.
Article
de Ko
| WPRIM
| ID: wpr-722530
Bibliothèque responsable:
WPRO
ABSTRACT
OBJECTIVE: To assess the effect of vitamin K2 in addition to risedronate on postmenopausal osteoporosis METHOD: We enrolled 21 postmenopausal osteoporosis women (age: 65.2+/-7.8 years). Ten subjects received risedronate (35 mg, weekly) and vitamin K2 (45 mg, daily) and eleven subjects only received risedronate. They all received calcium citrate 2,130 mg and vitamin D 600 IU daily. The duration of treatment was 7.7+/-1.4 months. Bone mineral density (BMD) of lumbar spine and both femurs, serum osteocalcin and urine deoxypyridinoline were examined at baseline and after treatment. RESULTS: After treatment, BMD, serum osteocalcin and urine deoxypyridinoline were improved in each group but there was no statistical difference between the groups. CONCLUSION: There was no evidence of the benefit of vitamin K2 in addition to risedronate in bone metabolism on postmenopausal osteoporosis.
Mots clés
Texte intégral:
1
Indice:
WPRIM
Sujet Principal:
Rachis
/
Vitamine D
/
Vitamines
/
Densité osseuse
/
Ostéocalcine
/
Ostéoporose post-ménopausique
/
Citrate de calcium
/
Vitamine K2
/
Fémur
/
Acide risédronique
Limites du sujet:
Female
/
Humans
langue:
Ko
Texte intégral:
Journal of the Korean Academy of Rehabilitation Medicine
Année:
2006
Type:
Article